FDA Allows Phase 2 Study For Sound Pharmaceuticals' Novel Drug To Prevent Chemotherapy Induced Hearing Loss

�Sound Pharmaceuticals (SPI) has
received FDA notification that it whitethorn proceed with its Phase II survey to
forbid chemotherapy induced hearing red. The Ph-II study will enroll 80
patients with advanced nous and neck, and non-small cell lung cancer at the
National Center for Rehabilitative Auditory Research at the Veterans
Administration Hospital and the Oregon Health and Science University in
Portland, Oregon.



Hearing red due to ototoxic medications such as chemotherapy,
antibiotics or loop diuretics oft results in permanent and progressive
disablement. Furthermore, the combined habit of these ototoxic agents is
contraindicated, often limiting their clinical utility. Symptoms of
ototoxicity include hearing loss, tinnitus, dizziness, lightheadedness and
difficulty understanding speech. Historically, the incidence of cisplatin
or carboplatin-induced sense of hearing loss was widely under estimated or reported
due to unequal testing or a want of coverage. Recently, a new
behavioral audiometric protocol has been developed and employed to test an
individual's sensitive range for ototoxicity (SRO). This involves pure-tone
audiometry at very specific steps within a person's upper berth range of hearing.
With the SRO protocol, several studies right away report an incidence of
ototoxicity of 85-92% for cisplatin and carboplatin receiving cancer
patients, an incidence that is much greater than previously reported. One
of the goals of this Ph-II study is to shorten the incidence and severity of
the ototoxicity in platinum receiving cancer patients as measured by
pure tone audiometry victimisation the SRO protocol, distortion product otoacoustic
emissions (DPOAEs) and the tinnitus disablement inventory. DPOAEs are a
measure of outer hair cell single-valued function in the inner spike and ar another
sensitive and specific measure of ototoxicity.



In several preclinical studies, SPI has showed that its novel
chemoprotectant drug product, a humble molecule that mimics and induces
Glutathione Peroxidase activity was vital in preventing ototoxicity
patch not interfering with the chemotherapy treatment. In unmatchable rodent fashion model
of crab, the chemoprotectant enhanced the tumoricidal bodily process of
cisplatin.


Sound Pharmaceuticals, Inc.
http://www.soundpharma.com



More info

• Kids in U.S. still taking cough and cold meds despite warnings
• Megalodon had the mightiest bite
• Toxins found in Mars soil
• Laughter threatens woman’s health
• Ethical dilemma

Kim Robertson and Singh Kaur

   
Artist: Kim Robertson and Singh Kaur

   Genre(s): 
New Age
   

---

Discography:


   
 Crimson Collection Vol. 6 and 7

   Year: 1991   
Tracks: 2


   
 Crimson Collection Vol. 4 and 5

   Year: 1991   
Tracks: 3


   
 Crimson Collection Vol. 1 and 2

   Year: 1991   
Tracks: 2

---